Form 424B4 - Prospectus [Rule 424(b)(4)]:
SEC Accession No. 0001213900-21-005637
Filing Date
2021-02-01
Accepted
2021-02-01 11:52:11
Documents
15

Document Format Files

Seq Description Document Type Size
1 PROSPECTUS ea134268-424b4_nlspharma.htm 424B4 1978762
2 GRAPHIC image_001.jpg GRAPHIC 14073
3 GRAPHIC image_004a.jpg GRAPHIC 30789
4 GRAPHIC image_005.jpg GRAPHIC 34402
5 GRAPHIC image_006.jpg GRAPHIC 14916
6 GRAPHIC image_007.jpg GRAPHIC 17745
7 GRAPHIC image_008.jpg GRAPHIC 11253
8 GRAPHIC image_009.jpg GRAPHIC 22650
9 GRAPHIC image_010.jpg GRAPHIC 15414
10 GRAPHIC image_011.jpg GRAPHIC 18536
11 GRAPHIC image_012.jpg GRAPHIC 23274
12 GRAPHIC image_013.jpg GRAPHIC 46910
13 GRAPHIC image_014.jpg GRAPHIC 13369
14 GRAPHIC image_015.jpg GRAPHIC 46220
15 GRAPHIC image_016.jpg GRAPHIC 95983
  Complete submission text file 0001213900-21-005637.txt   2540056
Mailing Address ALTER POSTPLATZ 2 STANS V8 CH-6370
Business Address ALTER POSTPLATZ 2 STANS V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 424B4 | Act: 33 | File No.: 333-236797 | Film No.: 21575552
SIC: 2834 Pharmaceutical Preparations